Literature DB >> 10655108

The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis.

X Xing1, S C Wang, W Xia, Y Zou, R Shao, K Y Kwong, Z Yu, S Zhang, S Miller, L Huang, M C Hung.   

Abstract

Because HER-2/neu overexpression is important in cancer development, we looked for a method of suppressing the cell transformation mediated by HER-2/neu overexpression. We have identified that the DNA-binding protein PEA3, which is encoded by a previously isolated gene of the ets family, specifically targeted a DNA sequence on the HER-2/neu promoter and downregulated the promoter activity. Expression of PEA3 resulted in preferential inhibition of cell growth and tumor development of HER-2/neu-overexpressing cancer cells. This is a new approach to targeting HER-2/neu overexpression and also provides a rationale to the design for repressors of diseases caused by overexpression of pathogenic genes.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10655108     DOI： 10.1038/72294

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  43 in total

Review 1.  Mediterranean diet, olive oil and cancer.

Authors:  Ramón Colomer; Javier A Menéndez
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

Review 2.  Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis.

Authors:  Natasza A Kurpios; Nancy A Sabolic; Trevor G Shepherd; Gina M Fidalgo; John A Hassell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

3.  Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.

Authors:  C Giordano; S Catalano; S Panza; D Vizza; I Barone; D Bonofiglio; L Gelsomino; P Rizza; S A W Fuqua; S Andò
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

Review 4.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

5.  beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.

Authors:  S Hapke; M Gawaz; K Dehne; J Köhler; J F Marshall; H Graeff; M Schmitt; U Reuning; E Lengyel
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

6.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.

Authors:  F J Fleming; E Myers; G Kelly; T B Crotty; E W McDermott; N J O'Higgins; A D K Hill; L S Young
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

8.  A reason why the ERBB2 gene is amplified and not mutated in breast cancer.

Authors:  Daniel Birnbaum; Fabrice Sircoulomb; Jean Imbert
Journal:  Cancer Cell Int       Date:  2009-02-18       Impact factor: 5.722

9.  Pea3 transcription factors and wnt1-induced mouse mammary neoplasia.

Authors:  Rebecca Baker; Claire V Kent; Rachel A Silbermann; John A Hassell; Lawrence J T Young; Louise R Howe
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

10.  The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins.

Authors:  B L Smith; D Chin; W Maltzman; K Crosby; G N Hortobagyi; S S Bacus
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.